Deargen

Developer of AI-based drug discovery platform for rare and intractable diseases

placeSeoul, Seoul, South Korea calendar_todayFounded 2016 groups39 employees language deargen.me

Registered entities

Innovation

49 patent families (7 granted) — focus: Physics & computing, Human necessities, Chemistry & metallurgy; filing pace steady. Cited 218 times.

YearFilings
20192
20201
20211
20222
202321
202422
20255

Investor mix

5 investors on record; lead investors include Nvester, The Wells Investment, Korean Development Bank, T S Investment.

Investor typeCountShare
Venture capital120%
Private equity120%
Other / undisclosed360%
Coming soon